Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Regulatory Science Gets The Flu (Funding) In HHS Overhaul Of Bioterror Product Development

This article was originally published in The Pink Sheet Daily

Executive Summary

Agency to receive $170 million for regulatory sciences initiative in recognition of the need for smother development pathway for medical countermeasures.

You may also be interested in...



Speedy Vaccine Production Among Goals Of FDA's Budget Proposal For Countermeasures

FDA plans to expand its medical countermeasures program beyond pandemic influenza with the infusion of $70 million requested in the fiscal year 2012 budget sent to Capitol Hill by the Obama Administration Feb. 14.

Speedy Vaccine Production Among Goals Of FDA's Budget Proposal For Countermeasures

FDA plans to expand its medical countermeasures program beyond pandemic influenza with the infusion of $70 million requested in the fiscal year 2012 budget sent to Capitol Hill by the Obama Administration Feb. 14.

With Federal Dollars Scarce, FDA May Fundraise For Regulatory Science Initiative

Industry and other federal agencies could end up helping fund Commissioner Margaret Hamburg’s Regulatory Science Initiative, as FDA searches for money outside the appropriations process.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS071059

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel